These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 30707502)

  • 21. Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia.
    Ravandi F; Arana Yi C; Cortes JE; Levis M; Faderl S; Garcia-Manero G; Jabbour E; Konopleva M; O'Brien S; Estrov Z; Borthakur G; Thomas D; Pierce S; Brandt M; Pratz K; Luthra R; Andreeff M; Kantarjian H
    Leukemia; 2014 Jul; 28(7):1543-5. PubMed ID: 24487412
    [No Abstract]   [Full Text] [Related]  

  • 22. Idarubicin is superior to daunorubicin in remission induction of de novo acute myeloid leukemia patients with high MDR1 expression.
    Shi P; Zha J; Guo X; Chen F; Fan Z; Huang F; Meng F; Liu X; Feng R; Xu B
    Pharmacogenomics; 2013 Jan; 14(1):17-23. PubMed ID: 23252945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of adults with acute myelogenous leukemia: prospective evaluation of high-dose cytarabine in consolidation chemotherapy and with bone marrow transplantation.
    Champlin R; Ho W; Winston D; Decker R; Greenberg P; Burnison M; Holly FE; Gale RP
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):1-6. PubMed ID: 2438775
    [No Abstract]   [Full Text] [Related]  

  • 24. Idarubicin plus attenuated high-dose cytosine arabinoside in the treatment of relapsed and refractory acute leukemia.
    Cavanna L; Di Stasi M; Fornari F; Civardi G; Sbolli G; Moretto M; Buscarini L
    Eur J Haematol; 1990 Sep; 45(3):180-1. PubMed ID: 2226733
    [No Abstract]   [Full Text] [Related]  

  • 25. Increased tumor growth and drug uptake predicts for response to continuous infusion high-dose cytarabine.
    Burke PJ; Karp JE
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):55-9. PubMed ID: 3859933
    [No Abstract]   [Full Text] [Related]  

  • 26. Idarubicin plus cytarabine as first-line treatment of acute nonlymphoblastic leukemia.
    Lambertenghi-Deliliers G; Annaloro C; Cortelezzi A; Cortellaro M; Della Volpe A; Maiolo AT; Mozzana R; Pogliani E; Pozzoli E; Polli EE
    Semin Oncol; 1989 Feb; 16(1 Suppl 2):16-20. PubMed ID: 2928806
    [No Abstract]   [Full Text] [Related]  

  • 27. Acute myeloid leukaemia with abnormal eosinophil precursors without inversion 16.
    Rashidi A; Roullet MR
    Br J Haematol; 2012 Sep; 158(5):561. PubMed ID: 22758220
    [No Abstract]   [Full Text] [Related]  

  • 28. Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia.
    Sackmann-Muriel F; Fernández-Barbieri MA; Santarelli MT; Matus-Ridley M; Rosso A; Negri-Aranguren P; Cerutti I; Gomel M; Kvicala R
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):34-8. PubMed ID: 8290970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Acute myelogenous leukemia complicated with severe tumor lysis syndrome after a single day of idarubicin/cytarabine chemotherapy].
    Kikuchi T; Miyata A; Fujii S; Kikuchi T
    Rinsho Ketsueki; 2003 Nov; 44(11):1113-6. PubMed ID: 14689878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bullous leukaemia cutis.
    Kikuchi N; Yamamoto T
    Eur J Dermatol; 2012; 22(1):148-9. PubMed ID: 22237386
    [No Abstract]   [Full Text] [Related]  

  • 31. A randomized comparison of immediate versus delayed application of G-CSF in induction therapy for patients with acute myeloid leukemia unfit for intensive chemotherapy.
    von Lilienfeld-Toal M; Hahn-Ast C; Kirchner H; Flieger D; Dölken G; Glasmacher A
    Haematologica; 2007 Dec; 92(12):1719-20. PubMed ID: 18056004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia.
    Low M; Lee D; Coutsouvelis J; Patil S; Opat S; Walker P; Schwarer A; Salem H; Avery S; Spencer A; Wei A
    Intern Med J; 2013 Mar; 43(3):294-7. PubMed ID: 22757980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of Acute Myeloid Leukemia with Idarubicin, Cytarabine and Cladribine.
    Wiedower E; Jamy O; Martin MG
    Anticancer Res; 2015 Nov; 35(11):6287-90. PubMed ID: 26504064
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Idarubicin in acute leukemia: results of US trials.
    Berman E; Raymond V; Gee TS; Kempin SJ; Gulati S; Andreeff M; Gabrilove J; Young CW; Clarkson BD; Wiernik PH
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():49. PubMed ID: 2713561
    [No Abstract]   [Full Text] [Related]  

  • 35. Acute myeloid leukemia with a novel CPSF6-RARG variant is sensitive to homoharringtonine and cytarabine chemotherapy.
    Zhang Z; Jiang M; Borthakur G; Luan S; Huang X; Tang G; Xu Q; Ji D; Boyer AD; Li F; Huang R; You MJ
    Am J Hematol; 2020 Feb; 95(2):E48-E51. PubMed ID: 31769058
    [No Abstract]   [Full Text] [Related]  

  • 36. Gelatinous transformation of marrow in a case of acute myelogenous leukemia post-chemotherapy.
    Feng CS
    Am J Hematol; 1991 Nov; 38(3):220-2. PubMed ID: 1951321
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bilateral ear Sweet's syndrome in a case with relapse acute myeloblastic leukemia.
    Disel U; Paydas S; Yavuz S; Tuncer I; Alpay R
    Leuk Res; 2006 Mar; 30(3):364. PubMed ID: 16157374
    [No Abstract]   [Full Text] [Related]  

  • 38. Major response of PNH to an AML chemotherapy protocol.
    Füreder W; Sperr WR; Gleixner K; Thalhammer R; Schwarzinger I; Hoermann G; Kornauth C; Grünberger B; Valent P
    Ann Hematol; 2018 Aug; 97(8):1487-1488. PubMed ID: 29568989
    [No Abstract]   [Full Text] [Related]  

  • 39. An evaluation of no-treatment decisions in patients with newly diagnosed acute myeloid leukemia.
    Brandwein JM; Hallett D; Karkhaneh M; Zhu N; Liew E; Bolster L; Hamilton M; Patterson J; Taparia M; Wu C; Van Slyke T; Bankar A; Saini L
    Am J Hematol; 2021 Jan; 96(1):E17-E20. PubMed ID: 33021743
    [No Abstract]   [Full Text] [Related]  

  • 40. A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients.
    Martínez-Cuadrón D; Gil C; Serrano J; Rodríguez G; Pérez-Oteyza J; García-Boyero R; Jiménez-Bravo S; Vives S; Vidriales MB; Lavilla E; Pérez-Simón JA; Tormo M; Colorado M; Bergua J; López JA; Herrera P; Hernández-Campo P; Gorrochategui J; Primo D; Rojas JL; Villoria J; Moscardó F; Troconiz I; Linares Gómez M; Martínez-López J; Ballesteros J; Sanz M; Montesinos P;
    Leuk Res; 2019 Jan; 76():1-10. PubMed ID: 30468991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.